arg bpc 157 BPC-157 – FDA considers widening access to

Clinicians prescribing BPC-157 should document the following in the medical record: the off-label nature of the prescription, the absence of human clinical trial data, the FDA's position on compounded BPC-157, the patient's prior treatment history with approved therapies, and the patient's written informed consent

Study Design Considerations Research protocols must specify exact dosing schedules and concentrations

Plausible hypotheses That is the tension at the heart of the current peptide boom: plausible biology can generate excitement long before it generates reliable clinical evidence

2019 May 27;3(2):200-214